Taysha Gene Therapies Receives Orphan Drug Designation from

Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis

Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis

biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Suyash Prasad , Head Of Research , Queen University , Development Of Taysha , European Commission , Drug Administration , Nasdaq , Exchange Commission , Taysha Gene Therapies Inc , European Union , Ut Southwestern Gene Therapy Program , Gene Therapies , Chief Medical Officer , Orphan Drug , Rare Pediatric Disease , Gene Therapy Program , Private Securities Litigation Reform Act , Annual Report , Quarterly Report ,